Simbec-Orion MBO Underpins Build And Buy Strategy

Private equity group CBPE Capital acquires majority stake in UK CRO and will finance expansion into US; deal provides Welsh Life Sciences Investment Fund with first exit.

Closed up finger on keyboard with word CLINICAL TRIALS

With backing from private equity group CBPE Capital, Simbec-Orion is on the hunt for assets to increase its US presence. The private equity group, through its £459m CBPE Capital Fund IX, has financed a management buyout at the CRO and is committed to providing further finance for further international growth and expansion by Simbec-Orion. CBPE acquired its majority stake by buying the stake owned by the Welsh Government-backed Welsh Life Sciences Investment Fund.

Created in 2014 by the merger of Simbec Research and Orion Group, Simbec-Orion has been on a fast growth trajectory seeing revenues increase from £13.2m in 2014 to an expected...

More from Clinical Trials

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By 

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By 

New CEO Renée Aguiar-Lucander is marking her mark.

Gilead Ready To Go After Hepatitis D Again

 
• By 

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

More from R&D

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By 

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.